News >

CML Paradigm Transforms With New Treatments, Potential for TKI Discontinuation

Dylann Cohn-Emery
Published: Friday, Aug 09, 2019

Jorge E. Cortes, MD

Jorge E. Cortes, MD

The second-generation TKIs dasatinib (Sprycel), nilotinib (Tasigna), and bosutinib (Bosulif), along with the emerging potential for TKI discontinuation, have transformed the treatment paradigm for chronic myeloid leukemia (CML), said Jorge Cortes, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication